Susan Catherine Lee MD, Presenter: Nothing to Disclose

Nicole Antonia Lamparello MD, Abstract Co-Author: Nothing to Disclose

Alampady Krishna Prasad Shanbhogue MD, MBBS, Abstract Co-Author: Nothing to Disclose

Christine O. Menias MD, Abstract Co-Author: Nothing to Disclose

Neeraj Lalwani MD, Abstract Co-Author: Nothing to Disclose

Srinivasa R. Prasad MD, Abstract Co-Author: Nothing to Disclose

1. To provide a current update on diagnosis and management of gestational trophoblastic disease (GTD). 2. US has low sensitivity but high positive predictive value in diagnosing molar pregnancy. MR can accurately show degree of uterine myometrial and extrauterine invasion in malignant GTD, although patients with low b-hCG levels (<500 mIU/mL) often have normal MR findings. 3.18F-FDG PET can assess tumor after chemotherapy, and confirm treatment response or recurrent tumor.

GTD is a relatively uncommon, yet almost completely curable, pregnancy-related entity arising from uncontrolled growth of placental tissue. Hydatidiform mole constitutes benign but premalignant disease. With the advent of routine US in first trimester, most molar pregnancies now present with findings of early pregnancy failure rather than classic “cluster of grapes”. Malignant forms invasive mole, choriocarcinoma, placental site trophoblastic tumor and epithelioid trophoblastic tumor. A current update on epidemiology, etiopathogenesis, natural history, clinical and pathological manifestations of GTD will be presented. A comprehensive update on the role of imaging in the diagnosis and staging of GTD will be presented with implications on management.

http://abstract.rsna.org/uploads/2014/14004475/14004475_1hza.pdf

Lee, S, Lamparello, N, Shanbhogue, A, Menias, C, Lalwani, N, Prasad, S, Gestational Trophoblastic Disease: A Current Update on Imaging and Management.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14004475.html